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Concomitant use of adjuvant tamoxifen (TAM) and radiation therapy (RT) is not widely accepted. We aim to assess whether this
treatment is associated with an increased risk of developing subcutaneous fibrosis after conservative or radical surgery in breast
cancer patients. We analysed 147 women with breast cancer treated with adjuvant RT, and who were included in the KFS 00539-9-
1997/SKL 00778-2-1999 prospective study aimed at evaluating the predictive value of CD4 and CD8 T-lymphocyte apoptosis for the
development of radiation-induced late effects. TAM (20mgday
 1) with concomitant RT was prescribed in 90 hormone receptor-
positive patients. There was a statistically significant difference in terms of complication-relapse-free survival (CRFS) rates at 3 years,
48% (95% CI 37.2–57.6%) vs 66% (95% CI 49.9–78.6%) and complication-free survival (CFS) rates at 2 years, 51% (95% CI 40–
61%) vs 80% (95% CI 67–89%) in the TAM and no-TAM groups, respectively. In each of these groups, the CRFS rates were
significantly lower for patients with low levels of CD8 radiation-induced apoptosis, 20% (95% CI 10–31.9%), 66% (95% CI 51.1–
77.6%), and 79% (95% CI 55–90.9%) for CD8 p16, 16–24, and 424%, respectively. Similar results were observed for the CFS
rates. The concomitant use of TAM with RT is significantly associated with an increased incidence of grade 2 or greater subcutaneous
fibrosis; therefore, caution is needed for radiosensitive patients.
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The efficacy of radiotherapy (RT) in the treatment of malignant
disease is limited by the need to avoid severe and nonreversible
late damage to normal tissues. Nevertheless, the positive impact of
RT in several tumours such as breast cancer makes its use
inevitable. Indeed, postoperative RT decreases the risk of
locoregional recurrence and is associated with improved survival
in high-risk premenopausal and postmenopausal breast cancer
patients given adjuvant chemotherapy or tamoxifen (TAM),
respectively (Overgaard et al, 1997, 1999).
The use of adjuvant TAM in postmenopausal breast carcinoma
patients as an adjunct to primary surgery is well established. The
benefits from this treatment have been shown in lymph node-
negative as well as lymph node-positive patients, both in terms of a
prolonged recurrence-free survival and an increase in overall
survival, especially in women presenting with oestrogen receptor-
positive tumours (EBCTCG et al, 1998). The role of TAM is still
under discussion in ductal carcinoma in situ of the breast after
complete resection (Fisher et al, 1999; Houghton et al, 2003).
The interaction of TAM and RT remains poorly defined. TAM
appears to exert its cytostatic activity at least partly through
competitive inhibition at the oestrogen receptor, resulting in
segregation of cells into G0/G1 phase of the cell cycle (Osborne et al,
1983). Because relatively less radiosensitivity has been observed in
early G1 (Sinclair, 1968), a hypothetical concern is raised with
TAM whether its combination with radiotherapy results in the
radioprotection of tumour clonogens of hormonally responsive
and unresponsive breast carcinoma cells at dose levels typical of
those used clinically (Wazer et al, 1989). However, in this study,
the cell cultures were grown in a medium containing phenol red
and foetal bovine serum, two sources of exogenous oestrogenic
compounds (Butler et al, 1981; Page et al, 1983; Berthois et al,
1986; Germain and Harbrioux, 1993). This fact complicates the
interpretation of the resultant radiation survival curves (Gould and
Clifton, 1978). In contrast to these reports, no significant
differences were observed in terms of radiosensitivity for
oestradiol-stimulated or 4-hydroxytamoxifen-inhibited cultures
plated under growth-stimulating conditions immediately after
irradiation or following an additional 24h under oestrogen-free
conditions (Sarkaria et al, 1994). Clearly, under defined hormonal
conditions (Cormier and Jordan, 1989), no protective effect of
the active TAM metabolite, 4-hydroxytamoxifen, was observed
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l(Sarkaria et al, 1994). In addition, irradiation and TAM may
modify the oestrogen and progesterone receptor content in the
cytosol in breast cancer cells and that could explain their change in
radiation sensitivity (Paulsen et al, 1996). Results from a study in
tumour-bearing rats (Kantorowitz et al, 1993) receiving fractio-
nated RT, TAM, or both showed that, in contrast to in vitro results,
the combination treatment reduced the probability of subsequent
tumour development.
In so far as the preclinical data with breast cancer cells can be
extrapolated to the clinical situation, no alteration in responsive-
ness would be expected following TAM exposure. Although no
clinical trials have been designed to address specifically the effect
of concurrent TAM on the response to conventional RT, results
from clinical trials which included treatment arms with and
without TAM suggest that no deleterious consequences accom-
panied TAM treatment. Results from the National Surgical
Adjuvant Breast Project (NSABP)-B14 trial suggested that TAM
and RT may have a synergistic interaction since patients receiving
both therapies experienced a higher probability of local control
(Fisher et al, 1989). In the Danish Breast Cancer Cooperative
Group 82c randomised trial, RT and TAM were associated with a
lower risk of locoregional recurrence and improved survival in
high-risk postmenopausal breast cancer patients after mastectomy
and limited axillary dissection, after only 1 year of adjuvant TAM
treatment (Overgaard et al, 1999). However, TAM has been
reported to lead to worse cosmesis in women who underwent
conservative surgery, RT, and had received TAM (Wazer et al,
1992) but not in others (Taylor et al, 1995; Fowble et al, 1996).
Wazer et al (1997) found no adverse effect of TAM on cosmesis in
an updated analysis of 498 women who were treated with breast-
conserving therapy. Adjuvant tamoxifen was administered to 130
patients, beginning 1–6 weeks after irradiation. More extensive
regional lymphatic irradiation was administered to the TAMþ
group. Chemotherapy was administered to 15% of TAMþ and
28% (P¼0.003) of TAM  patients. There were no significant
differences between the groups with respect to tumour size, re-
iexcision, total excised tissue volume, final margin status, total
radiation dose, or use of interstitial implant boost. There was no
significant difference between the TAMþ and TAM  groups in
the overall distribution of cosmetic scores (P¼0.18). The 5-, 7-,
and 10-year actuarial local failure rates for TAMþ vs TAM 
patients were 0 vs 3.1%, 1.9 vs 5.4%, and 1.9 vs 8.4%, respectively.
Multivariate regression analyses of potentially confounding vari-
ables revealed no significant associations between tamoxifen and
either cosmetic outcome or local failure.
Our goal in this study was to evaluate the relationship between
the concomitant administration of TAM and adjuvant RT and the
risk of developing subcutaneous fibrosis after conservative or
radical surgery in breast cancer patients. The analysis was based
on patients participating in a large prospective study of 399
patients where we evaluated the correlation between the level of
radiation-induced apoptosis of CD4 and CD8 lymphocytes and late
side effects (Ozsahin et al, 2003).
PATIENTS AND METHODS
Design of the study
All patients included in the KFS 00539-9-1997/SKL 00778-2-1999
prospective study (Ozsahin et al, 2003) were used in evaluating the
predictive value of CD8 T-lymphocyte apoptosis on the develop-
ment of radiation-induced late side effects, notably fibrosis.
Among the 399 patients, 147 women presented with breast cancer.
Our objective was to assess, in this population, whether the risk of
developing subcutaneous fibrosis after conservative or radical
surgery and adjuvant RT was increased by the concomitant
administration of TAM.
Radiation-induced apoptosis
Heparinised whole blood (7ml) was obtained from consenting
patients participating in the study, diluted 1:10 in RPMI 1640
medium (Life Technologies, Basel, Switzerland) containing 20%
foetal bovine serum (Readysysteme, Zurzach, Switzerland), and
was divided into two 3.5-ml aliquots and placed in 25-cm
2 (60ml)
flasks. These aliquots were irradiated at room temperature under
oxic conditions with 0- and 8Gy using an Oris IBL 137 cesium
source (CIS-Bio International, Gif-sur-Yvette, France) at a dose
rate of 2.67cGys
 1. Following irradiation, the preparations were
incubated at 371Ci n5 %C O 2. After 48h, the contents of each flask
were distributed into four 5-ml test tubes and then centrifuged at
1300r.p.m. for 5min at room temperature. Most of the supernatant
was aspirated and the pellet resuspended in approximately 200ml
of the remaining solution. A volume of 10ml of FITC-conjugated
anti-CD8 monoclonal antibody were added (Becton-Dickinson,
Basel, Switzerland). Following incubation for 20min at room
temperature, 4ml of 1:10 diluted lysis solution (Becton Dickinson,
Basel, Switzerland) was added to the suspension, and the speci-
mens were left for 10min at room temperature in the dark to
promote lysis of erythrocytes. The cells were then centrifuged at
1450r.p.m. for 5min, the supernatant was aspirated, and the cells
were washed once with 4ml phosphate-buffered saline (PBS;
Becton Dickinson, Basel, Switzerland). After another round of
centrifugation (1450r.p.m. for 5min), the supernatant was
aspirated. The cells were resuspended in 200ml of FACSFlow
(Becton Dickinson, Basel, Switzerland) phosphate buffer to which
5ml of propidium iodide (PI) stock (1mgml
 1 in PBS) was added
to stain the DNA. Then, 50ml of RNase stock solution (1mgml
 1)
was added, and the samples were incubated at room temperature
for 5min before flow cytometric measurement. Samples were
measured using a FACScan flow cytometer (Becton-Dickinson, San
Jose, CA, USA) with a 488nm, 15mW argon-ion laser (Coherent,
Santa Clara, CA, USA). Data analysis were performed via a two-
step procedure using the CellQuest software (Becton-Dickinson,
Basel, Switzerland) on a Macintosh computer. Data from each
lymphocyte sample were acquired immediately after the staining
procedure. Four-parameter acquisition permitted discrimination
of the different subpopulations of lymphocytes. Forward and side
light scattering and stain-induced fluorescence at two different
wavelengths (530nm green, and 640nm red) were simultaneously
measured from each cell. Using forward scatter (FSC) vs side
scatter (SSC) dot plots, three subpopulations of leukocytes (mono-,
granulo-, and lymphocytes) as well as the cell debris could be
distinguished, and the lymphocytes were selected. After staining
the cells with FITC-conjugated antibodies (green fluorescence) to
identify lymphocyte cell-type and PI (red fluorescence) to quantify
cellular DNA content, the CD8-positive cells were identified by
simultaneous measurement of the two laser-induced fluorescent
signals. Apoptotic lymphocytes were defined as those cells staining
positively for their cell-type-specific antibodies, and displaying
reduced DNA content and cell size. These lymphocytes were
previously examined for apoptotic cells by the TUNEL assay
(Ozsahin et al, 1997). Data for at least 10000cellssample
 1 were
acquired.
Treatment modalities
All patients had staging investigations including chest X-ray,
bone scan, and liver enzymes to rule out metastatic disease at
diagnosis. Initial values of age, TNM 2002 staging according to
the American Joint Committee on Cancer staging system for
breast cancer (Singletary et al, 2002), histopathology, type of
surgery, margins, and menopausal status were noted. Surgical
treatment consisted of breast-conserving surgery (any type) or
mastectomy and axillary dissection in 118 (80.3%) and 29 patients,
respectively.
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was delivered to the breast and, when indicated, to the regional
lymphatics. Treatment portals consisted of opposing tangential
fields using cobalt or 6–18MV photons. Both tangential fields
were treated daily. A physical lead block or asymmetrical
collimation was used for half-beam blocking. The breast dose,
routinely prescribed to the midline, was 50Gy at 2Gy fractions,
with a varying percentage of compensating filters and/or bolus. All
patients received a 16-Gy boost (20Gy in the case of suspicious
surgical margins) to the primary tumour bed using 6–15MeV
electrons.
The 29 mastectomy patients received chest-wall irradiation
using opposing tangential fields with cobalt or 6–18MV photons
using half-beam blocking. Both tangential fields were treated daily.
The chest wall dose was 50Gy at 2Gy fractions using compensating
filters and/or bolus (one-third to half of the treatment). A 4–
6MeV electron boost of 10–16Gy was given to the surgical scar in
high-risk patients. Nodal irradiation, when indicated (mostly
supraclavicular and internal mammary nodes), was given at a total
dose of 50Gy in 25 fractions. Supraclavicular lymph nodes were
treated with a split anterior oblique (10–151) beam at a dose of
50Gy calculated at the depth of 3cm. Internal mammary nodal
irradiation in some patients was administered using a separate
anterior field, namely, 25Gy at a 4-cm depth with 6MV photons,
followed by 25Gy at the 100% isodose line using tailored electrons
(mostly 12MeV) according to the position of the internal
mammary lymph nodes as assessed on the CT-scan. When
indicated, axillary lymph nodes were included in the anterior
supraclavicular field, and the missing axillary midline dose was
completed using a posterior axillary field.
Post- or perimenopausal women who were shown to have
oestrogen receptor and/or progesterone receptor-positive tumours
(ER and/or PgR¼10fmolmg
 1 cytosol protein; or¼10% of the
tumour cells positive by an immunocytochemical assay) were
prescribed 20mg of tamoxifen (TAM) daily. In all cases, TAM
therapy was initiated the month before or the day of the start of
RT. Premenopausal women (n¼11) with receptor-positive tu-
mours were given 20mg of tamoxifen daily for 5 years and an
LHRH analogue monthly for at least 2 years. None of the patients
who received TAM received adjuvant chemotherapy.
Women who were shown to have oestrogen receptor- and
progesterone receptor- negative tumours with axillary lymph node
metastasis received six cycles of chemotherapy with cyclopho-
sphamide, fluorouracil, and methotrexate, or with cyclopho-
sphamide and adriamycin. No treatment with concomitant
chemotherapy and irradiation was given. Typically, the patients
began RT 3 weeks after the completion of chemotherapy.
Radiation-induced assessment of side effects
During treatment, acute toxicity was evaluated according to WHO
and CTC-NCI v2.0 criteria. All patients were visited every 6 months
for 2 years. During the follow-up visits, late side effects were
graded according to the RTOG/EORTC scale (Cox et al, 1995). The
time at which the maximal grade of late side effects was observed,
that is, before 2 years had elapsed, was retained for analysis
(RTOG-1). Patients were revaluated for late side effects at 2 years
(RTOG-2) by a second physician (DA). The assessment of toxicity
was blinded to treatment.
Statistical analysis
Data were summarised by frequencies and percentages for
categorical variables and by means, standard deviations, median,
and range for continuous variables. Three categories of absolute
change in the percent CD8 cells in apoptosis before and after
exposure to 8Gy of irradiation were constructed around the
median value. The Kruskal–Wallis test was used to compare the
continuous variables, and the w
2-test was used to compare the
categorical variables between the two groups of patients with or
without TAM.
All survival estimations were computed from the date of start of
radiotherapy. Overall survival (OS), relapse-free survival (RFS),
complication-free survival (CFS), and complication-relapse-free
survival (CRFS) curves were estimated by the Kaplan–Meier
method using the following first event definitions, death for OS,
local or distant recurrence or death for RFS, grade 2 or 3 fibrosis
for CFS, and any event for CRFS. The median follow-up was also
estimated by the Kaplan–Meier method.
For OS, patients alive at the last follow-up visit were censored.
For RFS, patients alive and relapse-free were censored at the last
follow-up visit. For CFS, patients alive who never experienced a
grade 2 or more fibrosis were censored at the last follow-up visit.
Patients who relapsed before a grade 2 or greater fibrosis were
censored at the time of relapse. For CRFS, patients alive and
relapse-free who never experienced a grade 2 or greater fibrosis
were censored at the last follow-up visit. The log-rank test was
used to identify significant categorical variables for each of the
survival curves. A step-wise Cox proportional hazards regression
model was used for multivariate analysis. A P-value less than 0.05
was considered statistically significant. The data were expressed as
means 795% confidence intervals (CI). All statistical tests were
two-sided.
Table 1 Patient characteristics
No
tamoxifen
N¼57 (%)
Tamoxifen
N¼90 (%)
All patients
N¼147 (%) P-value
Age, years
Mean (s.d.) 55.5 (1.61) 58.7 (1.21) 57.4 (11.78)
Median (range) 55.0 (26–80) 59.0 (35–82) 57.0 (26–82)
o60 40 (70.2) 46 (51.1) 86 (58.5)
X60 17 (29.8) 44 (48.9) 61 (41.5) 0.022
Histopathology
a
IDC 36 (63.2) 67 (74.5) 103 (70.1)
ILC 7 (12.3) 18 (20.0) 25 (17.0)
DCIS 10 (17.5) 3 (3.3) 13 (8.8)
Others 4 (7.0) 2 (2.2) 6 (4.1) 0.008
TNM
b
T in situ 10 (17.9) 2 (2.3) 12 (8.4)
T1 28 (50.0) 49 (56.3) 77 (53.8)
T2 10 (17.9) 27 (31.0) 37 (25.9)
T3 4 (7.1) 4 (4.6) 8 (5.6)
T4 4 (7.1) 5 (5.8) 9 (6.3) 0.005
c
N N0 40 (71.4) 46 (52.9) 86 (60.1)
N1 12 (21.4) 39 (44.8) 51 (35.7)
N2 2 (3.6) — 2 (1.4)
N3 2 (3.6) 2 (2.3) 4 (2.8) 0.027
d
M M0 56 (100.0) 87 (100.0) 143 (100.0)
M 1 ——— —
Type of surgery
Mastectomy 12 (21.1) 17 (18.9) 29 (19.7)
Conservative 45 (78.9) 73 (81.1) 118 (80.3) 0.748
Tumorectomy 31 (54.4) 49 (54.4) 80 (54.4)
Quadrantectomy 14 (24.5) 24 (26.7) 38 (25.9) 0.931
Margins
Clear 52 (91.2) 86 (95.6) 138 (93.9)
Positive or close 5 (8.8) 4 (4.4) 9 (6.1) 0.286
Menopausal status
Pre 81 (4.0) 11 (12.2) 19 (12.9)
Peri or post 49 (86.0) 79 (87.8) 128 (87.1) 0.75
aIDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; DCIS¼ductal
carcinoma in situ.
bInitial TNM was not available for four patients but these patients
completed their treatments and continued to be visited at each medical evaluation.
None of them were M1 during the follow-up visits.
cTest on Tis/T1/T2/T3+T4.
dTest
on N0 vs N1+N2+N3.
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cumulative incidence of each first failure type, grade 2 or greater
fibrosis, and relapse. These estimates may be different from those
obtained from the inverse Kaplan–Meier survival function
estimates since the event-time distributions of each failure type
was taken into account rather than censored independently of the
other event (Arriagada et al, 1992).
RESULTS
Patient characteristics
Patient characteristics of the 147 patients are presented in Table 1.
There were significantly more patients 60 years or older in the
group that received TAM than in the group that did not receive
TAM (49 vs 30%). Patients who received TAM were significantly
more likely to have had pathologically positive axillary lymph
nodes (47.1 vs 28.6%), larger tumour size (41 vs 32% XT2), and
more invasive lobular carcinoma histopathologic subtypes (20 vs
12%). No difference was identified regarding margin measure-
ments. Most of the patients were postmenopausal (87%) with no
difference between the two groups. The extent of surgery applied
to both groups was similar with 80% of patients having had breast-
conserving surgery.
Treatment delivery
The radiation therapy characteristics are presented in Table 2. All
but two patients (99%) received a dose rate of 2Gy per fraction.
The intensity of RT administered was similar for the two groups
with no significant difference in the total dose of radiation, type of
energy (cobalt or X-rays) delivered, volume of the irradiated
breast, or the calculated dose at the surface of the breast. Median
treatment duration was 47 days (range 17–70).
All patients receiving TAM were hormone receptor positive, and
none received adjuvant chemotherapy. Chemotherapy was admi-
nistered for hormone receptor-negative patients with positive
axillary nodes and who were younger than 65 years old (12
patients, 21%). The CD8-radiation-induced apoptosis character-
istics are presented in Table 2. The overall mean difference (7s.d.)
Table 2 Treatment delivery and characteristics of CD8 radiation-induced apoptosis
No tamoxifen N¼57 Tamoxifen N¼90 All patients N¼147 P-value
Duration, days
Mean (s.d.) 45.4 (0.99) 46.9 (0.70) 46.3 (7.02)
Median (range) 46.0 (17–57) 48.0 (23–70) 47.0 (17–70) 0.187
Dose (Gy)
o35 1 (1.7%) 1 (1.1%) 2 (1.4%)
50 8 (14.0%) 4 (4.4%) 12 (8.2%)
60 1 (1.7%) 1 (1.1%) 2 (1.4%)
66 42 (73.7%) 80 (88.9%) 122 (82.9%)
X68 5 (8.8%) 4 (4.4%) 9 (6.1%)
Dose/fraction (Gy)
1.8 — 1 (1.1%) 1 (0.7%)
2 56 (98.2%) 89 (98.9%) 145 (98.6%)
3 1 (1.8%) — 1 (0.7%)
Energy
Breast-conserving surgery
Cobalt
60 33 (73.3%) 47 (64.4%) 80 (67.8%)
X6 (MV) 12 (26.7%) 26 (35.6%) 38 (32.2%) 0.312
Mastectomy
Cobalt
60 6 (50.0%) 10 (58.8%) 16 (55.2%)
X6 (MV) 6 (50.0%) 7 (41.2%) 13 (44.8%) 0.638
Volume of the irradiated breast (ml)
Breast-conserving surgery N¼45 N¼73 N¼118
Mean (s.d.) 1134.4 (323.84) 1323.7 (613.56) 1251.5 (528.81)
Median (range) 1071.0 (602.3–2018.3) 1224 (480–4032) 1127.0 (480–4032) 0.059
Mastectomy N¼12 N¼17 N¼29
Mean (s.d.) 911.2 (394.52) 1075.9 (455.6) 1007.8 (431.9)
Median (range) 831.4 (514.3–1930.5) 966.9 (675–2268) 900.0 (514.3–2268) 0.320
Dose of the surface of the breast (Gy)
Breast-conserving surgery N¼45 N¼73 N¼118
Mean (s.d.) 92.3 (10) 95.1 (6.6) 94.1 (8.1)
Median (range) 94.1 (50.6–104.7) 95.4 (68.6–105.8) 95.3 (50.6–105.8) 0.067
Mastectomy N¼12 N¼17 N¼29
Mean (s.d.) 95.4 (7.76) 94.6 (7.4) 94.9 (7.44)
Median (range) 95.1 (83.2–107.2) 95.1 (79.1–107.2) 95.1 (79.1–107.2) 0.762
CD8 (before RT*, %)
Mean (s.d.) 9.1 (1) 7.9 (0.73) 8.4 (7.18)
Median (range) 6.5 (1.3–38.2) 5.6 (0.8–35.3) 6.3 (0.8–38.2) 0.134
CD8 (after 8Gy, %)
Mean (s.d.) 31.9 (1.74) 26.6 (1.1) 28.7 (11.8)
Median (range) 29.7 (10.2–69.8) 26.2 (5.8–59.6) 28.2 (5.8–69.8) 0.024
CD8 Difference, %
Mean (s.d.) 22.9 (1.31) 18.7 (1.03) 20.3 (9.96)
Median (range) 21.8 (6.2–51.9) 17.6 (3.4–55.7) 20.0 (3.4–55.7) 0.008
CD8 (%)p16 13 (22.8%) 37 (41.1%) 50 (34%)
16–24 21 (36.8%) 31 (34.4%) 52 (35.4%)
424 23 (40.4%) 22 (24.4%) 45 (30.6%) 0.041
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lbefore and after radiotherapy was 20.3 (79.96) with a statistically
significant difference observed between the two groups, 18.7 and
22.9 in the TAM and no TAM groups, respectively. Significantly
more patients included in the TAM group had CD8radio-induced
apoptosis p16% (41%) than patients not receiving TAM (23%).
Acute toxicity
All patients experienced at least a grade 1 acute WHO side effect
with 23.1% grade 3 of breast skin toxicity. No difference between
the TAMþ and TAM  groups was observed. According to the
CTC-NCI v2.0 classification, only five patients (3.4%) experienced
grade 3radiation dermatitis with no statistical difference between
the two groups. No grade 4 toxicity was observed. Finally, neither
WHO nor NCI-CTC v2.0 acute toxicities were correlated with
CD8radiation-induced apoptosis.
Relapse-free and overall survival
The median follow-up was 29 months (range: 23–79). Ten patients
relapsed (6.8%), five of whom died (3.4%). The 3-year survival rate
and the relapse-free survival rates were 97% (95% CI 88–99%) and
91% (95% CI 81–95%), respectively.
Late side effects
One patient was not evaluated for late side effects before 2 years
because of early relapse. Four patients were followed up for less
than 2 years and were not clinically examined for late side effects.
Late side effects according to the RTOG scale are presented in
Table 3. A total of 135 patients (92.5%) had at least a grade 1 RTOG
side effect before the first 2 years of follow-up. Four patients
treated with TAM experienced early grade 3 toxicities: three
subcutaneous fibrosis and one telangectasia. Among these four
patients, all remained grade 3 at 2 years, and none relapsed. In all,
36 patients had grade 2 subcutaneous toxicity before 2 years.
Among these patients and at 2 years, 29 remained grade 2, two
decreased to grade 1, five increased to grade 3. At 2 years, 129
patients (90.2%) had at least grade 1 toxicity. Overall, 14 patients
experienced 16 grade 3 skin and/or subcutaneous side effects
within two years, 11 subcutaneous fibrosis and five skin side
effects. Among them, two patients had both grade 3 skin and
subcutaneous side effects.
Complication-relapse-free survival
Complication-relapse-free survival according to prognostic factors
is presented in Table 4. CRFS rates were similar for all patient
characteristics except for treatment with TAM and CD8radiation-
induced apoptosis. There was a statistically significant difference at
3 years in terms of CRFS rates: 48% (95% CI 37.2–57.6%) vs 66%
(95% CI 49.9–78.6%) in the TAM and no-TAM groups,
respectively. In each of these groups, CRFS rates were significantly
lower for patients with low levels of CD8 radiation-induced
apoptosis, 20% (95% CI 10–31.9%), 66% (95% CI 51.1–77.6%),
and 79% (95% CI 55–90.9%) for CD8 p16, 16–24%, and 424%,
respectively.
Complication-free survival
Complication-free survival according to prognostic factors is
presented in Table 5. CFS rates were similar for all patient
characteristics except for treatment with TAM and CD8radiation-
induced apoptosis. There was a statistically significant difference
in CFS rates at 2 years, 51% (95% CI 40–61%) vs 80% (95% CI 67–
89%) in the TAM and no-TAM groups respectively. In each of
these groups, the CFS rates were significantly lower for patients
with low levels of CD8radiation-induced apoptosis: 23% (95% CI
12–36%), 76% (95% CI 61–85%), and 91% (95% CI 78–97%) for
CD8 p16, 16–24, and 424%, respectively. A multivariate analysis
using the Cox proportional hazards regression model showed a
significant increase in the risk of grade 2 or greater fibrosis in the
group of patients treated with TAM, with a hazard ratio of 2.1 (95%
CI 1.08–4.12, P¼0.029), as well as in the group of patients
considered as potentially more radiosensitive (CD8 apoptosis
p16) (Table 6). The incidence of grade 2 or greater fibrosis was
higher and at the limit of statistical significance in the group of
patients with CD8 apoptosis p16 treated with TAM, 31 out of 37
(84%) compared to no-TAM, seven out of 13 (54%). No grade 3
side effects were observed for patients with CD8 424%.
Cumulative incidence rates for each failure type according to
treatment are presented in Table 7 and Figure 1. The 2-year
complication-relapse-free survival rate was 54%, indicating that
46% of patients experienced either a grade 2 or 3 RTOG fibrosis, or
relapse as a first event before 2 years (Table 4). For example, the 2-
year cumulative incidence rates in the group of patients with CD8
T-lymphocyte apoptosis p16 and treated with TAM was 83% for
grade 2 or more fibrosis and 3% for relapse, which adds up to an
overall incidence of 86%, the complement of the CRFS rate. In all
patients, the relapse components were similarly distributed
between the three categories of CD8, with an estimated cumulative
incidence of 4, 7.7, and 2.2%, respectively.
DISCUSSION
The concept that the inherent radiosensitivity of both normal cells
and tumour cells varies from one individual to another is well
Table 3 RTOG late side effects
No tamoxifen Tamoxifen All patients
RTOG-1 N¼56 (%) N¼90 (%) N¼146
a (%)
Skin
Gr0 14 (25.0) 23 (25.6) 37 (25.3)
Gr1 30 (53.6) 35 (38.9) 65 (44.5)
Gr2 12 (21.4) 31 (34.4) 43 (29.5)
Gr3 — 1 (1.1) 1 (0.7)
Gr4 — — —
GrX2 12 (21.4) 32 (35.5) 44 (30.2)
Subcutaneous tissue
Gr0 33 (58.9) 33 (36.7) 66 (45.2)
Gr1 15 (26.8) 26 (28.9) 41 (28.1)
Gr2 8 (14.3) 28 (31.1) 36 (24.6)
Gr3 — 3 (3.3) 3 (2.1)
Gr4 — — —
GrX2 8 (14.3) 31 (34.4) 39 (26.7)
RTOG-2 N¼56 (%) N¼87 (%) N¼143
b (%)
Skin
Gr0 15 (26.8) 21 (24.1) 36 (25.2)
Gr1 26 (46.4) 31 (35.6) 57 (39.8)
Gr2 13 (23.2) 32 (36.8) 45 (31.5)
Gr3 2 (3.6) 3 (3.5) 5 (3.5)
Gr4 — — —
GrX2 15 (26.8) 35 (40.3) 50 (35.0)
Subcutaneous tissue
Gr0 25 (44.6) 21 (24.1) 46 (32.1)
Gr1 21 (37.5) 24 (27.6) 45 (31.5)
Gr2 10 (17.9) 31 (35.6) 41 (28.7)
Gr3 — 11 (12.7) 11 (7.7)
Gr4 — — —
GrX2 10 (17.9) 42 (48.3) 52 (36.4)
Gr¼grade; RTOG-1¼the time at which the highest grade of late side effects was
observed RTOG-2, late side effects at 2 years.
aOne patient was not evaluated
because of early relapse.
bFour patients relapsed before 2 years and were not
evaluated for RTOG-2.
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lestablished (Fertil and Malaise, 1981). This is clinically relevant
because large patient-to-patient variation in radiation morbidity
has been documented, even after RT with a fixed dose-fractiona-
tion schedule (Tucker et al, 1992; Bentzen et al, 1993; Bentzen,
1997). The data published so far on the cellular and molecular
factors underlying acute or late tissue reactions appeared to be
contradictory and suggest that there is no clear-cut relationship
between cellular radiosensitivity and the risk of acute or late
reactions; consequently, no test has been recommended up to now
for predicting the risk or the severity of late reactions in breast
cancer (Burnet et al, 1992; Brock et al, 1995; Jones et al, 1995;
Johansen et al, 1996; Russell et al, 1998; Kiltie et al, 1999; Barber
et al, 2000; Peacock et al, 2000; Oppitz et al, 2001). To confirm our
first preclinical and retrospective studies on the correlation of
radiation-induced CD4 and CD8 T-lymphocyte apoptosis (RTLA)
and late side effects after RT (Ozsahin et al, 1997), we assessed
prospectively RTLA by the prediction of individual intrinsic
radiosensitivity of 399 consenting patients treated with curative RT
for miscellaneous cancers (Ozsahin et al, 2003). RTLA significantly
predicted grades 2 and 3 late effects (Po0.0001). Considering
grade 3 late toxicity, patients with late effects (n¼25) showed CD4
or CD8 radiation-induced apoptosis below the median
(Po0.0001). The area under the curve of the receiver–operator
characteristic curves of CD4 and CD8 apoptosis considered
separately or CD4 and CD8 analyzed together were 0.84, 0.89,
and 0.92, respectively (Ozsahin et al, 2003). To our knowledge, this
is the first rapid predictive test based on lymphocyte apoptosis
confirmed prospectively in a large number of patients. We
considered CD8 more sensitive and more specific than CD4 T-
lymphocyte apoptosis. We therefore analysed in the present study,
the subgroup of 147 women who were treated for breast cancer by
RT with (concomitant) or without TAM, and stratified by CD8
radiation-induced apoptosis.
Our finding of the influence of TAM on subcutaneous fibrosis,
particularly in radiosensitive patients, is not supported by the
results of any other published studies. Wazer et al (1992) showed a
borderline significant trend, indicating an adverse impact of TAM
on cosmetic appearance, but these preliminary results were not
confirmed in their updated analysis (Wazer et al, 1997). Fowble
et al (1996) reported on 154 patients treated with TAM and found
no major adverse effect on cosmesis or complications. The timing
of the TAM with the initiation of RT was unknown for 111 patients.
In all, 23 patients received TAM during RT, and 20 began TAM
after the completion of RT. Taylor et al (1995) showed that the use
of adjuvant TAM did not appear to diminish the excellent cosmetic
outcomes, irrespective of whether it was administered concur-
rently or sequentially with RT. In a recent prospective randomised
study comparing breast pain after breast-conserving surgery and
TAM with or without RT (Rayan et al, 2003), the incidence and
severity of breast symptoms was similar at baseline in patients
subsequently randomised to the RT and no-RT arms of the study.
With lung fibrosis as an end point, contradictory reports have
indicated that TAM could result in potentiation of postradiation
normal tissue reactions (Bentzen et al, 1996; Huang et al, 2000; Koc
et al, 2002; Mahler, 2002; Christensen et al, 2003).
The dominant cause of cosmetic failure in the patients treated
with irradiation and TAM appeared to be retractive fibrosis. While
not immediately apparent, there may be a mechanistic link
between TAM therapy and postradiation normal tissue changes.
TAM has been found to stimulate in vitro the secretion in human
fibroblasts of the fibroblast mitogen, transforming growth factor b
(TGF-b) (Colletta et al, 1990). There is evidence to suggest that the
Table 4 Prognostic factors for complication (fibrosis XGr2) relapse-free survival (CRFS)
No tamoxifen N¼57 (%) P-value Tamoxifen N¼90 (%) P-value All patients N¼147 (%) P-value
CRFS rate (3 years) 66.4 47.8 54.0 0.0051
Age, years
o60 60.7 52.2 55.3
X60 79.4 0.20 43.2 0.25 53.1 0.46
Histopathology
a
IDC 64.8 46.3 52.6
ILC 68.6 38.9 43.3
DCIS 80.0 100.0 84.6
Others 75.0 0.86 100.0 0.22 83.3 0.12
TNM staging
T in situ 80.0 100.0 83.3
T1 75.0 48.9 58.4
T2 80.0 44.4 54.0
T3/T4 33.3 0.26 22.2 0.30 28.2 0.08
N N0 75.6 52.1 62.9
N1/N2/N3 58.3 0.27 38.5 0.28 43.6 0.04
M M0 70.6 — 45.9 — 55.5 —
Type of surgery
Mastectomy 65.6 47.1 54.4
Conservative
Tumorectomy 50.8 53.1 51.4
Quadrantectomy 85.7 0.31 37.5 0.41 55.3 0.93
Margins
Clear 70.0 48.8 55.9
Positive or close 30.0 0.15 25.0 0.39 29.6 0.23
Menopausal status
Pre 87.5 45.5 63.2
Peri or post 62.1 0.25 48.1 0.93 51.9 0.43
CD8p16 38.5 35.0 20.0
16–24 70.3 64.5 66.2
424 76.1 0.002 81.8 o0.001 78.8 o0.001
aIDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; DCIS¼ductal carcinoma in situ.
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mediated by TGF-b. Canney and Dean (1990) performed serial
biopsies on irradiated and nonirradiated postsurgical patients. In
four of the six irradiated patients, nontumour tissues within the
treatment area stained positive for TGF-b beginning 9 weeks after
therapy and continued to stain positive throughout the 40-week
duration of the study. The nonirradiated patients showed no
staining for TGF-b in non-tumour tissues. Therefore, if postradia-
tion fibrosis is partially mediated by TGF-b and the secretion of
this growth factor by fibroblasts is enhanced by TAM, then the
presence of TAM may accentuate postradiation fibrosis. As
postradiation changes in the breast may take years to stabilise
(Beadle et al, 1984; Olivotto et al, 1989), such an interaction would
not necessarily require the concomitant administration of RT and
TAM. Finally, RT and TAM are both separately involved in
initiating the skin fibrosis phenomenon by an increased produc-
tion of the transforming growth factor-beta1 (TGF-b1) (Butta et al,
1992; Martin et al, 1993; Border and Noble, 1994), but it is not clear
from our study whether the predominant effect of TAM is on the
induction of RT injury or whether it is through a post-RT
modification of the processing of RT injury in the tissue. We
recommend delaying the start of TAM after completion of RT
without reduced efficacy for the patients (Delozier et al, 1997), but
interactions between both treatments may occur, even if they are
separated in time (Parry, 1992; Bostrom et al, 1999).
In terms of local control, our data do not show any difference
between the two groups of patients treated by RT alone (three
patients) or concomitant RTþTAM (two patients). With a median
follow-up of 29 months, the small number of local failures in our
study lacks sufficient statistical power to allow the detection of a
significant difference. Several retrospective studies have assessed
the influence of TAM on local control and showed that TAM was
associated with either no difference or a modest enhancement of
local control (Rutqvist et al, 1992; Leborgne et al, 1995; Fowble
Table 5 Prognostic factors for complication (fibrosis XGr 2)-free survival (CFS) at 2 years
No tamoxifen N¼57 (%) P-value Tamoxifen N¼90 (%) P-value All patients N¼147 (%) P-value
CFS rate (2 years) 80.3 51.4 62.5 0.0007
Age, years
o60 76.8 56.0 65.6
X60 88.2 0.34 46.5 0.25 58.3 0.28
Histopathology
a
IDC 77.1 49.5 59.2
ILC 100.0 44.4 59.7
DCIS 80.0 100.0 84.6
Others 75.0 0.61 100.0 0.27 83.3 0.26
TNM staging
T in situ 80.0 100.0 83.3
T1 77.8 48.9 59.2
T2 90.0 50.4 61.5
T3/T4 72.9 0.84 37.5 0.60 55.0 0.47
N N0 78.0 52.1 64.0
N1/N2/N3 85.7 0.57 46.3 0.71 56.8 0.45
M M0 79.9 — 49.6 — 61.5 —
Type of surgery
Mastectomy 90.9 61.4 74.0
Conservative
Tumorectomy 71.0 54.9 61.2
Quadrantectomy 92.3 0.13 37.5 0.19 56.8 0.27
Margins
Clear 80.4 52.0 62.6
Positive or close 80.0 0.98 33.3 0.83 58.3 0.86
Menopausal status
Pre 87.5 45.5 63.2
Peri or post 79.1 0.59 52.2 0.88 62.5 0.83
CD8p16 46.1 14.7 23.1
16–24 85.0 69.7 75.9
424 95.6 0.001 86.4 o 0.001 91.1 o 0.001
aIDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; DCIS¼ductal carcinoma in situ.
Table 6 Cox multivariate regression analysis for complication (fibrosis
XGr 2)-free survival
Prognostic variable Hazard ratio 95% CI P-value
CD8
a p16 1
16–24 0.22 0.11–0.43 o0.001
424 0.08 0.03–0.24 o0.001
No tamoxifen 1
Tamoxifen 2.1 1.08–4.12 0.029
aPercentage of radiation-induced CD8 lymphocyte apoptosis.
Table 7 A 2-year cumulative incidence of the first event (fibrosis XGr
2) and relapse according to CD8 radiation-induced apoptosis
No tamoxifen (%) Tamoxifen (%) All patients (%)
Fibrosis XGr 2
CD8p16 53.8 83.7 76
16–24 14.3 29.1 23
424 4.3 13.6 8
Relapse
CD8p16 7.7 2.7 4
16–24 9.5 6.5 7.7
424 4.3 0 2.2
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let al, 1996; Christensen et al, 2003; Pierce et al, 2003). In these
studies, the timing and sequencing of TAM administration relative
to RT were either variable or not reported. The NSABP-B14 trial
randomised 2644 patients with negative axillary lymph nodes
between TAM and placebo. Breast-conserving surgery and RT were
performed on 1072 patients, with TAM administered after surgery
and during RT. There was a significant decrease in the breast
relapse rate at 5 years with TAM (Fisher et al, 1989). More recently,
Dalberg et al (1998) reported long-term results of adjuvant TAM in
lymph node-negative postmenopausal women treated with breast-
conserving surgery and postsurgical RT. The patients constituted a
separate stratum of a larger trial, the Stockholm Adjuvant
Tamoxifen Trial. TAM was started at the beginning of RT. In that
study, the addition of TAM to RT resulted in a reduced rate of
ipsilateral and contralateral breast tumour recurrences with a
median follow-up of 8 years. The cosmetic toxicity over a long
term was not mentioned by the authors.
Among the interesting questions arising from this study are
whether subcutaneous fibrosis might be prevented, or at least
reduced. First, our predictive radiation-induced lymphocyte
apoptosis assay seems to be highly specific and sensitive to
discriminate subgroups of patients as a function of their intrinsic
radiosensitivity. Further prospective studies are still necessary
before using this test in routine daily practice. Second, preliminary
results have shown that TGF-b antagonists may inhibit or reduce
the action of this growth factor (Border et al, 1990; Shah et al,
1992; Delanian et al, 1999; Lefaix et al, 1999; Delanian et al, 2003).
The significant reduction of chronic RT damage obtained with the
pentoxifylline and alpha-tocopherol combination (Delanian et al,
2003) does not support the concept that established RT sequelae
such as radiation-induced subcutaneous fibrosis are irreversible.
Third, evidence from the first analysis of the ATAC (Arimidex,
Tamoxifen Alone or in Combination Trialists Group) trial
supports the use of aromatase inhibitors such as anastrozole for
the adjuvant treatment of early breast cancer in postmenopausal
women (Baum et al, 2002). Our data show that in radiosensitive
patients, TAM should be delayed after completion of RT. Another
approach could be to replace TAM by an aromatase inhibitor. This
type of molecule has yet to be tested concomitantly with RT in a
clinical setting. Recently, we demonstrated the radiosensitisation
of breast cancer cells transfected with the aromatase gene by the
nonsteroidal aromatase inhibitor letrozole (Azria et al, 2003).
We conclude that the concomitant use of TAM with RT is
significantly associated with the incidence of subcutaneous fibrosis
but not telangiectasia. In patients receiving adjuvant hormonal
treatment, TAM and RT should only be administered concomi-
tantly with caution to radiosensitive patients.
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Figure 1 Cumulative incidence of grade 2 or greater fibrosis curves according to CD8 radiation-induced apoptosis and concomitant tamoxifen with
radiation therapy.
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